NBD AI Bulletin -- Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (the Company, SZ 300357, closing price: 59.29 yuan) announced on November 25 that as of November 24, 2020, the time set for the share reduction program has been halfway through. Board director and deputy general manager Ms. Zhang Lu did not reduce the Company's shares.

According to the semi-annual report of 2020, Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. mainly engages in pharmaceutical manufacturing, accounting for 99.34% of its revenue. 

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s chairman and general manager is Hu Gengxi, male, 56 years old, Chinese national, no permanent residence abroad, Ph.D.

Tips on "Stock Trends":

1. The number of shares held by northbound investors decreased by 1.3432 million in the past 30 days, representing 0.28% of the Company's circulating shares.

2. One batch of institutions (9 in total) conducted researches on the Company in the past 30 days.

3. The last share reduction announcement of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. was issued on October 28, 2020, and its share price rose 4.52% on the following trading day. The Company issued a total of 10 such announcements in the past 12 months. 

(By Tan Yuhan)

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.